J
Jianhua Chen
Researcher at Central South University
Publications - 70
Citations - 1720
Jianhua Chen is an academic researcher from Central South University. The author has contributed to research in topics: Medicine & Lung cancer. The author has an hindex of 12, co-authored 33 publications receiving 756 citations.
Papers
More filters
Journal ArticleDOI
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial
Yuankai Shi,Li Zhang,Xiaoqing Liu,Caicun Zhou,Shucai Zhang,Dong Wang,Qiang Li,Shukui Qin,Chunhong Hu,Yiping Zhang,Jianhua Chen,Ying Cheng,Jifeng Feng,Helong Zhang,Yong Song,Yi-Long Wu,Nong Xu,Jianying Zhou,Rongcheng Luo,Chunxue Bai,Ye-ning Jin,Wenchao Liu,Zhaohui Wei,Fenlai Tan,Yinxiang Wang,Lieming Ding,Hong Dai,Shunchang Jiao,Jie Wang,Li Liang,Weimin Zhang,Yan Sun +31 more
TL;DR: Icotinib was non-inferior to gefitinib in terms of progression-free survival and could be a new treatment option for pretreated patients with advanced non-small-cell lung cancer.
Journal ArticleDOI
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
Jing Huang,Jianming Xu,Chen Yun,Wu Zhuang,Yiping Zhang,Zhendong Chen,Jia Chen,Helong Zhang,Zuoxing Niu,Qingxia Fan,Lizhu Lin,Kangsheng Gu,Ying Liu,Yi Ba,Zhanhui Miao,Xiaodong Jiang,Ming Zeng,Jianhua Chen,Zhichao Fu,Lu Gan,Jun Wang,Xianbao Zhan,Tianshu Liu,Zhiping Li,Lin Shen,Yongqian Shu,Tao Zhang,Qing Yang,Jianjun Zou,Suxia Luo,Feng Peng,Gang Wu,Nong Xu,Lin Zhao,Dong Ma,Shukui Qin,Wei Ren,Enxiao Li,H. Lu,Yueyin Pan,Jianping Xiong,Ying Yuan,Yuxian Bai,Lei Chen,Yi Hu,Li Zhang,Yong Gao +46 more
TL;DR: Second-line camrelizumab significantly improved overall survival in patients with advanced or metastatic oesophageal squamous cell carcinoma compared with chemotherapy, with a manageable safety profile.
Journal ArticleDOI
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.
Caicun Zhou,Gongyan Chen,Yunchao Huang,Jianying Zhou,Lizhu Lin,Jifeng Feng,Zhe-Hai Wang,Yongqian Shu,Jianhua Shi,Yi Hu,Qiming Wang,Ying Cheng,Fengying Wu,Jianhua Chen,Xiaoyan Lin,Yongsheng Wang,Jian-An Huang,Jiuwei Cui,Lejie Cao,Yunpeng Liu,Yiping Zhang,Yueyin Pan,Jun Zhao,LiPing Wang,Jianhua Chang,Qun Chen,Xiubao Ren,Wei Zhang,Yun Fan,Zhiyong He,Jian Fang,Kangsheng Gu,Xiaorong Dong,Tao Zhang,Wei Shi,Jianjun Zou +35 more
TL;DR: The primary endpoint was met at the interim analysis, showing a statistically significant and clinically meaningful improvement in progression-free survival with camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in all patients, supporting camrelIZumabplus carboplasin and pemberrexed as a first-line treatment option for Chinese patients with advanced non-squamous NSCLC.
Journal ArticleDOI
Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study
Caicun Zhou,Xingya Li,Qiming Wang,Guanghui Gao,Yiping Zhang,Jianhua Chen,Yongqian Shu,Yanping Hu,Yun Fan,Jian Fang,Gongyan Chen,Jun Zhao,Jianxing He,Fengying Wu,Jianjun Zou,Xiaoyu Zhu,Xiang Lin +16 more
TL;DR: Pyrotinib showed promising antitumor activity and an acceptable safety profile in chemotherapy-treated patients with HER2-mutant NSCLC in a prospective, multicenter, open-label, single-arm, phase II study.
Journal ArticleDOI
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.
Yunpeng Yang,J. Zhou,Jianying Zhou,Jifeng Feng,Wu Zhuang,Jianhua Chen,Jun Zhao,Wei Zhong,Yanqiu Zhao,Yiping Zhang,Yong Song,Yi Hu,Zhuang Yu,Y. Gong,Yuan Chen,Feng Ye,Shucai Zhang,Lejie Cao,Yun Fan,Gang Wu,Yubiao Guo,Chengzhi Zhou,K. Ma,Jian Fang,Weineng Feng,Yunpeng Liu,Zhendong Zheng,Gaofeng Li,Ning Wu,Wei Song,Xiaoqing Liu,Shijun Zhao,Lieming Ding,Li Mao,Giovanni Selvaggi,Xiaobin Yuan,Yuanqing Fu,Tao Wang,Shanshan Xiao,Li Zhang +39 more
TL;DR: Ensigninib has activity and is well tolerated in patients with crizotinib-refractory, ALK-positive NSCLC, including those with brain metastases, and the role of ensartinib in patients in whom other second-generation ALK inhibitors have been unsuccessful warrants further studies.